Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Regenxbio (RGNX) over the last 12 years, with Q3 2025 value amounting to $525.2 million.

  • Regenxbio's Liabilities and Shareholders Equity rose 117.3% to $525.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 billion, marking a year-over-year decrease of 997.22%. This contributed to the annual value of $466.0 million for FY2024, which is 1881.3% down from last year.
  • Regenxbio's Liabilities and Shareholders Equity amounted to $525.2 million in Q3 2025, which was up 117.3% from $581.0 million recorded in Q2 2025.
  • Regenxbio's Liabilities and Shareholders Equity's 5-year high stood at $1.1 billion during Q4 2021, with a 5-year trough of $466.0 million in Q4 2024.
  • For the 5-year period, Regenxbio's Liabilities and Shareholders Equity averaged around $723.4 million, with its median value being $682.5 million (2023).
  • In the last 5 years, Regenxbio's Liabilities and Shareholders Equity skyrocketed by 8956.11% in 2021 and then tumbled by 3111.82% in 2023.
  • Quarter analysis of 5 years shows Regenxbio's Liabilities and Shareholders Equity stood at $1.1 billion in 2021, then decreased by 25.19% to $833.3 million in 2022, then plummeted by 31.12% to $574.0 million in 2023, then dropped by 18.81% to $466.0 million in 2024, then rose by 12.71% to $525.2 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $525.2 million for Q3 2025, versus $581.0 million for Q2 2025 and $490.9 million for Q1 2025.